Primary held the dominant position in the brain tumor diagnosis and therapeutics market in 2025, accounting for a 60.82% share. This leadership is maintained through the direct clinical focus placed on primary brain tumors within specialized diagnosis and treatment pathways, where timely imaging, pathology confirmation, and intervention planning are central to patient management. The primary segment also benefits from well-defined care workflows that connect diagnosis and therapeutics more tightly, supporting consistent demand across the brain tumor diagnosis and therapeutics market.

Secondary is emerging as the fastest-growing segment in the brain tumor diagnosis and therapeutics market as clinical attention increasingly expands toward metastatic brain involvement and the need for coordinated detection and treatment strategies. Its momentum is backed by the practical requirement to manage more complex cases that often need multidisciplinary evaluation, repeat imaging, and tailored therapeutic decisions. Compared with primary cases, the secondary segment is experiencing stronger uptake because it sits at the intersection of broader cancer management and brain-specific intervention, creating stronger growth in diagnostic and therapeutic utilization.

End Use Segment Analysis: Oncology Treatment Centers (Largest Segment) vs Hospitals (Fastest-Growing Segment)

With a 51.41% share in 2025, Oncology Treatment Centers represented the largest end-use segment in the brain tumor diagnosis and therapeutics market. Their leadership is rooted in concentrated cancer care delivery, where specialist teams, dedicated treatment infrastructure, and integrated diagnostic pathways support efficient management of brain tumor cases. These centers are structured to handle complex oncology workflows, which helps sustain their share in the brain tumor diagnosis and therapeutics market by aligning diagnosis, treatment planning, and therapeutic administration within one specialized setting.

Hospitals are the fastest-growing end-use segment in the brain tumor diagnosis and therapeutics market because they are often the first point of care for patients requiring urgent neurological assessment, imaging, and inpatient management. Growth is being reinforced by the expanding role of hospitals in handling complex and time-sensitive brain tumor cases that require coordination across neurology, radiology, surgery, and oncology functions. Relative to dedicated treatment centers, hospitals are gaining momentum through their broader access base and operational capacity to manage both diagnosis and immediate therapeutic intervention.